Biomarin Pharmaceutical (LTS:0HNC) Cash Flow for Dividends : $0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical Cash Flow for Dividends?

Biomarin Pharmaceutical's cash flow for dividends for the three months ended in Dec. 2024 was $0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2024 was $0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Biomarin Pharmaceutical Cash Flow for Dividends Historical Data

The historical data trend for Biomarin Pharmaceutical's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cash Flow for Dividends Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow for Dividends

Get a 7-Day Free Trial

Biomarin Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash Flow for Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Biomarin Pharmaceutical Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Biomarin Pharmaceutical Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » Cash Flow for Dividends

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Biomarin Pharmaceutical Headlines

No Headlines